Peterbio
Developer of gene and cell therapy technologies focused on cleavage-free, template-driven gene editing and sequence-specific gene repression. The organization emphasizes humanized protein components to reduce immunogenicity, applicability across multiple human cell types (hepatocytes, hematopoietic stem cells, B-cells, neurons), and approaches intended to enable repeat dosing for both acute and chronic genetic diseases. Engages in partnering and external scientific communication.
Industries
Nr. of Employees
small (1-50)
Peterbio
Boston, Massachusetts, United States, North America
Products
Cleavage-free template-driven gene editing platform
Platform architecture based on sequence-specific DNA-binding fusion proteins that open local DNA and enable single-stranded DNA templates to direct precise sequence changes without creating double-strand breaks.
Sequence-specific gene repression platform
Platform for gene repression that binds target loci to block transcription and achieve silencing for therapeutic applications.
RITDM™ 2.0 technology
A gene editing technology by PeterBio that repairs disease-causing genes and converts risk genes into protective genes, focusing initially on severe monogenic diseases and potentially applicable to chronic diseases with a genetic component.
T-LOCK™ gene repression technology
Gene repression technology that works by directly interacting with and binding to the gene to be repressed or silenced, preventing its transcription.
Cleavage-free template-driven gene editing platform
Platform architecture based on sequence-specific DNA-binding fusion proteins that open local DNA and enable single-stranded DNA templates to direct precise sequence changes without creating double-strand breaks.
Sequence-specific gene repression platform
Platform for gene repression that binds target loci to block transcription and achieve silencing for therapeutic applications.
RITDM™ 2.0 technology
A gene editing technology by PeterBio that repairs disease-causing genes and converts risk genes into protective genes, focusing initially on severe monogenic diseases and potentially applicable to chronic diseases with a genetic component.
T-LOCK™ gene repression technology
Gene repression technology that works by directly interacting with and binding to the gene to be repressed or silenced, preventing its transcription.
Services
Strategic collaborations to apply the company's gene editing and gene regulation technologies in therapeutic development.
Development and optimization of ex vivo editing procedures for therapeutic cell types such as B-cells and hematopoietic stem cells.
Strategic collaborations to apply the company's gene editing and gene regulation technologies in therapeutic development.
Development and optimization of ex vivo editing procedures for therapeutic cell types such as B-cells and hematopoietic stem cells.
Expertise Areas
- Gene and cell therapy development
- Template-driven cleavage-free gene editing
- Ex vivo genome editing and cell engineering
- Therapeutic development for monogenic and genetically driven diseases
Key Technologies
- Template-driven cleavage-free gene editing
- Human DNA-binding arrays (zinc finger arrays)
- Helicase beta-wing fusion proteins to locally open DNA
- Single-stranded DNA correction templates
News & Updates
Company presentation of a cleavage-free gene-editing technology at the Cell & Gene Meeting on the Med.
Publication describing the company's gene editing technology.
Announcement of Dirk Hondmann joining as CEO.
Company presentation of a cleavage-free gene-editing technology at the Cell & Gene Meeting on the Med.
Publication describing the company's gene editing technology.
Announcement of Dirk Hondmann joining as CEO.